Vasculitis describes a group of rare diseases where the immune system attacks blood vessels, causing inflammation that can damage organs. Some types affect large vessels like the aorta, others target small vessels in the kidneys or lungs. Treatment typically involves steroids and immunosuppressive drugs, with newer targeted therapies now approved for several forms.
What's actually going on in research
Trials are testing therapies that deplete specific immune cells or block inflammation signals, aiming to control disease with fewer side effects than long-term steroids. Studies are exploring BTK inhibitors, IL-6 blockers, complement inhibitors, and combinations that might allow steroid tapering. Researchers are also working to identify biomarkers that predict flares and treatment response.
Targeted immune therapies
Drugs like rituximab and tocilizumab target specific parts of the immune system and have shown promise in several vasculitis types. Trials are testing whether newer targeted drugs can replace or reduce steroid use.
Complement inhibition
Drugs blocking the complement system are being tested in ANCA-associated vasculitis, where this immune pathway drives kidney damage. Early results suggest they may prevent organ injury.
Biomarker development
Researchers are identifying blood tests that signal disease activity before organs are damaged. These could allow earlier treatment adjustments and predict which patients need more aggressive therapy.
What to know before you search
Eligibility typically depends on vasculitis type, disease activity level, organ involvement, ANCA status in some forms, and prior treatments tried.
What types of trials are currently open
- Induction therapy trials — Testing new drugs to bring active vasculitis under control quickly, often comparing them to standard steroid-based treatment.
- Maintenance trials — Testing whether new drugs can keep vasculitis quiet long-term while reducing or eliminating steroid use.
- Steroid-sparing trials — Studies testing whether targeted therapies allow faster tapering of steroids or avoid them entirely, reducing side effects.
- Relapse prevention trials — Testing treatments in people whose vasculitis is controlled, to see if they prevent future flares.
- Biomarker studies — Following people with vasculitis to identify blood or tissue markers that predict flares or treatment response.
Recently added Vasculitis trials
Try dietary changes to help reduce ear ringing from Behçet disease
otogic problems are varied in bechet disorder, tinnnitus is one of these problems. obesity may increase this probelm
Receive massage techniques to reduce vein inflammation risk
Phlebitis is a clinical condition that develops as a complication of peripheral venous catheter use. Peripheral venous catheterization is a common clinical procedure performed in hospitalized patients, as it provides vascular access for the administration of medications, blood products, and contrast media for diagnostic imaging studies. The pathophysiology of phlebitis involves inflammation of the vascular intima, leading to luminal narrowing and impaired blood flow. These changes are clinically manifested by local signs of inflammation, including erythema, edema, and pain, which have been objectively assessed using several validated clinical assessment scales.
Find Vasculitis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.